- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00362700
Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201
January 30, 2017 updated by: Bukwang Pharmaceutical
An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of Retreated Clevudine in Chronic Hepatitis B Patients Who Received Clevudine in L-FMAU-201
The purpose of this study is to determine the safety and antiviral activity of Clevudine, when retreated to patients previously treated with Clevudine
Study Overview
Study Type
Interventional
Enrollment
33
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guro-gu
-
Seoul, Guro-gu, Korea, Republic of
- Korea University Guro Hospital
-
-
Jongno-Gu
-
Seoul, Jongno-Gu, Korea, Republic of
- Seoul National University Hospital
-
-
Seoul
-
Dogok-dong, Kangnam-gu, Seoul, Korea, Republic of
- Yongdong Severance Hospital
-
Ilwon-dong, Songpa-gu, Seoul, Korea, Republic of
- Samsung Medical Center
-
Mok-dong, Yangcheon-gu, Seoul, Korea, Republic of
- Ehwa Womans University Mokdong Hospital
-
Pungnap-dong, Kangnam-gu, Seoul, Korea, Republic of
- Seoul ASAN Medical Center
-
-
Songpa-Gu, Seoul
-
Pungnab2-dong, Songpa-Gu, Seoul, Korea, Republic of
- Asan Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who received clevudine in L-FMAU-201 clinical trial (phase IIb)
- Female of childbearing potential must have a negative serum ( b-HCG) pregnancy test within 14 days of starting therapy.
- Patient is able to give written informed consent prior to study start and to comply with the study requirements.
- Patients who met the following criteria after completion of the Week 48 visit were to have additional follow-up visits at Weeks 54 and 60: 1) had received no additional therapy since completion of 24-week treatment of clevudine and 2)experienced a > 1 log10 decrease from baseline in HBV DNA at Week 48
Exclusion Criteria:
- HBV DNA negative (< 4,700 copies/mL) consistently at the last 2 visit (at least 2 consecutive visits, at one month interval)
- Patient is currently receiving antiviral immunomodulatory or corticosteroid therapy.
- Patients previously treated with lamivudine, lobucavir, adefovir or any other investigational nucleoside for HBV infection after cessation of treatment in L-FMAU-201 study.
- Patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy.
- Patient is coinfected with HCV, HDV or HIV.
- Patient with clinical evidence of cirrhosis or hepatocellular carcinoma (®-Fetoprotein) Evaluation will be based on alpha-fetoprotein primarily. If alpha-fetoprotein level is suggestive of cirrhosis or hepatocellular carcinoma, confirmation will be made with sonography etc.
- Patient is pregnant or breast-feeding.
- Patient is unwilling to use an "effective" method of contraception during the study and for up to 3 months after the use of study drug ceases. For males, condoms should be used. Females must be surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal or using at least a medically acceptable barrier method of contraception (i.e., IUD, barrier methods with spermicide or abstinence)
- Patient has a clinically relevant history of abuse of alcohol or drugs.
- Patient has a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease.
- Patient has creatinine clearance less than 60mL/min as estimated by the following formula:
(140-age in years) (body weight [kg])/(72) (serum creatinine [mg/dL]) [Note: multiply estimates by 0.85 for women]
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Antiviral activity- Change from baseline in HBV DNA (log10)
|
Safety- Laboratory tests, Adverse Events, Vital Signs, ECG
|
Secondary Outcome Measures
Outcome Measure |
---|
Biochemical improvement (ALT normalization)
|
Antiviral activity- Proportion of patients with HBV DNA below the assay Limit of Detection(<4,700 copies/mL by Digene Hybrid Capture II)
|
Serology: Proportion of patients with HBeAg loss,Seroconversion rate (HBeAg loss and anti-HBe gain)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2003
Study Completion
October 1, 2005
Study Registration Dates
First Submitted
August 8, 2006
First Submitted That Met QC Criteria
August 8, 2006
First Posted (Estimate)
August 10, 2006
Study Record Updates
Last Update Posted (Estimate)
February 1, 2017
Last Update Submitted That Met QC Criteria
January 30, 2017
Last Verified
June 1, 2006
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- L-FMAU-204
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unknown
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
-
Ain Shams UniversityCompleted
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingChronic Hepatitis b | Cirrhosis Due to Hepatitis BChina
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
Clinical Trials on Clevudine
-
Bukwang PharmaceuticalCompleted
-
Bukwang PharmaceuticalTerminatedHepatitis BKorea, Republic of
-
Bukwang PharmaceuticalTerminatedHepatitis BKorea, Republic of
-
Triangle PharmaceuticalsUnknownHepatitis BUnited States, Canada, China, France, Singapore
-
French National Agency for Research on AIDS and...Gilead Sciences; PharmassetTerminatedHBe Negative Chronic Hepatitis B | Hepatitis B Viral InfectionFrance
-
Bukwang PharmaceuticalCompletedChronic Hepatitis BKorea, Republic of
-
Bukwang PharmaceuticalCompletedHBeAg(+) Chronic Hepatitis BKorea, Republic of
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Bukwang PharmaceuticalCompleted
-
Bukwang PharmaceuticalCompletedChronic Hepatitis BKorea, Republic of